Drug intelligence / Profile preview

IBI3005

Development stage: Phase 2
Lead developer: Suzhou Innovent Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI3005 is a bispecific antibody-drug conjugate (ADC) developed by Innovent Biologics for the treatment of advanced malignant solid tumors. It is designed to target both EGFR and HER3, leveraging a dual mechanism to enhance anti-tumor efficacy. The drug is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity are being evaluated in patients with unresectable or locally advanced solid tumors. The primary goal of these studies is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on IBI3005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI3005.

Explore the full profile